Basic Information
WELLBUTRIN SR TABLETS 150 mg
TABLET, FILM COATED
Regulatory Information
SIN10983P
June 16, 1999
Prescription Only
Therapeutic
ORAL
August 10, 2023
June 3, 2025
XN06AX12
Company Information
GLAXOSMITHKLINE PTE LTD
GLAXOSMITHKLINE PTE LTD
Active Ingredients
Strength: 150 mg
Detailed Information
Contraindications
**Contraindications** _WELLBUTRIN SR_ is contraindicated in patients with hypersensitivity to bupropion or any of the other components of the preparation. _WELLBUTRIN SR_ is contraindicated in patients with a seizure disorder. _WELLBUTRIN SR_ is contraindicated in patients undergoing abrupt discontinuation of alcohol or sedatives. _WELLBUTRIN SR_ tablets contain bupropion and should not be administered to patients currently being treated with any other preparation containing bupropion as the incidence of seizures is dose dependent. _WELLBUTRIN SR_ is contraindicated in patients with a current or previous diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was seen in this patient population when an immediate release form of bupropion was administered. Concomitant use of _WELLBUTRIN SR_ and monoamine oxidase inhibitors (MAOIs) is contraindicated. At least 14 days should elapse between discontinuation of MAOIs and initiation of treatment with _WELLBUTRIN SR_ tablets.
Indication Information
**Indications** _WELLBUTRIN SR_ is indicated for the treatment of major depressive episodes.